Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Shruti Joshi, Trisha Singh, David E. Newby, et al.
Heart (2021) Vol. 107, Iss. 13, pp. 1032-1038
Open Access | Times Cited: 137

Showing 1-25 of 137 citing articles:

Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Annemarie B. van der Aart‐van der Beek, Rudolf A. de Boer, Hiddo J.L. Heerspink
Nature Reviews Nephrology (2022) Vol. 18, Iss. 5, pp. 294-306
Open Access | Times Cited: 114
Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes
Moh’d Rasheed Abu-Qaoud, Ashish Kumar, Tushar Tarun, et al.
JACC. Clinical electrophysiology (2023) Vol. 9, Iss. 10, pp. 2109-2118
Open Access | Times Cited: 47
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, et al.
Free Radical Biology and Medicine (2024) Vol. 213, pp. 19-35
Open Access | Times Cited: 25
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, et al.
Current Heart Failure Reports (2021) Vol. 18, Iss. 5, pp. 315-328
Open Access | Times Cited: 76
Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells
Cheol Ho Park, Bin Lee, Myeonggil Han, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 42
Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases
Sachi Khemka, Aananya Reddy, Ricardo Isaiah Garcia, et al.
Ageing Research Reviews (2023) Vol. 91, pp. 102091-102091
Closed Access | Times Cited: 40
Obesity and novel management of inflammatory bowel disease
Jee Hyun Kim, Chang‐Myung Oh, Jun Hwan Yoo
World Journal of Gastroenterology (2023) Vol. 29, Iss. 12, pp. 1779-1794
Open Access | Times Cited: 33
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 30
Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond
Wei Yu, De Xie, Tetsuya Yamamoto, et al.
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 24, Iss. 2, pp. 327-343
Closed Access | Times Cited: 27
Sodium–glucose cotransporter‐2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies
Jan Biegus, Marat Fudim, Husam M. Salah, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 9, pp. 1526-1536
Open Access | Times Cited: 23
Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement
Fatmah R. Alsereidi, Zenith Khashim, Hezlin Marzook, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 5, pp. 102524-102524
Closed Access | Times Cited: 12
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling
Jingjing Zhang, X. Ye, Xuesong Liu, et al.
World Journal of Cardiology (2025) Vol. 17, Iss. 1
Closed Access | Times Cited: 1
The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 608-608
Open Access | Times Cited: 1
Sudden Cardiac Death in Diabetes and Obesity: Mechanisms and Therapeutic Strategies
Carol Ann Remme
Canadian Journal of Cardiology (2022) Vol. 38, Iss. 4, pp. 418-426
Open Access | Times Cited: 35
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
Rosanna Maccari, Rosaria Ottanà
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 10848-10881
Open Access | Times Cited: 31
Heart Failure in Patients with Chronic Kidney Disease
Αndrew Xanthopoulos, Adamantia Papamichail, Αlexandros Briasoulis, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 18, pp. 6105-6105
Open Access | Times Cited: 18
Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review
Sebastiano A. G. Lava, Craig Laurence, Alessandro Di Deo, et al.
Pediatric Drugs (2024) Vol. 26, Iss. 3, pp. 229-243
Closed Access | Times Cited: 6
Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials
Karan B. Bhanushali, Heena Asnani, Ambica Nair, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 9, pp. 102664-102664
Open Access | Times Cited: 6
NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
James P. Teuber, Kobina Essandoh, Scott L. Hummel, et al.
Antioxidants (2022) Vol. 11, Iss. 9, pp. 1822-1822
Open Access | Times Cited: 27
Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials
Peter A. McCullough, Alpesh Amin, Kevin M. Pantalone, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 11
Open Access | Times Cited: 25
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials
Yao Neng Teo, Adriel Z. H. Ting, Yao Hao Teo, et al.
American Journal of Cardiovascular Drugs (2022) Vol. 22, Iss. 3, pp. 299-323
Closed Access | Times Cited: 23
The role of Sodium-Glucose Transporter-2 Inhibitors (SGLT-2i) in preventing chronic obstructive disease exacerbation in patients with diabetes and COPD: An electronic health database analysis
Sushan Gupta, Avani Mohta, Alexa Lauinger, et al.
Heart & Lung (2024) Vol. 68, pp. 191-194
Closed Access | Times Cited: 5
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial
Massar Omar, J. Steen Jensen, Daniel Burkhoff, et al.
Circulation Heart Failure (2021) Vol. 15, Iss. 3
Open Access | Times Cited: 29
Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias
Antonis A. Manolis, Theodora A. Manolis, Helen Melita, et al.
Trends in Cardiovascular Medicine (2022) Vol. 33, Iss. 7, pp. 418-428
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top